)
)
)
Investing in the Future of Cardiometabolic and Longevity Therapies: Differentiating Pipelines
GLP-1 analogs have rewritten treatment standards and changed patients’ expectations related to obesity, yet even more tantalizing is growing evidence they could hold the key to broader improvements in cardiometabolic health and address other age-related diseases with implications for longevity R&D. This panel will highlight cellular and systemic approaches to elucidating the role of GLP-1 in multiple diseases associated with aging, discuss the clinical evidence that has generated excitement, and reveal how leaders in this nascent therapeutic area are approaching their pipelines.
Speakers
.png)
.jpg)
){kind=logo}
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
